Healthcare giant Siemens (NYSE:SI) saw declines in its healthcare division during Q1, with sales and profits down on a shaky quarter.
Wall Street Beat
Amedica looks to $35M U.S. IPO
Medical device company Amedica said it’s planning to put up nearly 3.2 million shares at $10 to $12 apiece in an initial public offering in the U.S.
Salt Lake City-based Amedica, which makes silicon nitride-based biomaterials for medical devices, said it plans to trade under the AMDA symbol on the NASDAQ exchange.
At the midpoint of the proposed offering range, Amedica would have an initial market capitalization of $143 million.
Rehab robots: Ekso Bionics goes public, raises $20.6M
California robotics company Ekso Bionics (OTCBB:EKSO) raised $20.6 million through a private placement offering and a reverse merger that made the company a wholly owned subsidiary of Ekso Bionics Holdings.
Unwinding in 2014: Analysts bullish on medtech’s E.U. prospects
The year ahead is looking to be an easier one for medical device companies navigating the European landscape, according to analysts with J.P. Morgan’s Europe Equity Research group.
Although austerity measures remain, major headwinds seem to be unwinding and patient volumes may finally be on the rebound as unemployment figures decline and consumer confidence grows.
Thoratec shareholder seeks class action over recall, blood clot study
St. Jude Medical shuffles the deck
Spinal: K2M finally goes public
Leesburg, Va.-based K2M Group Holdings announced today that it confidentially filed registration statements to launch an initial public offering of its common stock.
K2M, long the largest private spine implant company, did not provide details on potential timing, but said that the number of shares and price range for stock has yet to be determined.
Analysts warn of deeper impact of Medtronic’s renal denervation miss | MassDevice.com On Call
MASSDEVICE ON CALL — Medtech titan Medtronic (NYSE:MDT) took a risk when it bet nearly $1 billion on renal denervation pioneer Ardian years before its flagship device was slated to hit the U.S. market, and the recent foofaraw over the company’s missed clinical trial may have a cooling effect on other device companies, analysts warned.
ResMed slumps on disappointing U.S. sales and missed Q2 earnings
Covidien reports 19% profit dip and notches a win in J&J patent battle
Intuitive Surgical loses points after-hours after posting 2013 earnings
Sunnyvale, Calif.-based surgical robotics maker Intuitive Surgical (NSDQ:ISRG) lost a little Wall Street love today after the company reported 4th quarter and fiscal 2013 financial figures.